NTLA - Intellia Therapeutics Inc
IEX Last Trade
22.445
-0.555 -2.473%
Share volume: 1,395,897
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$23.00
-0.56
-2.41%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-02-23 | 2023-05-04 | 2023-08-03 | 2023-11-09 | 2024-02-22 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 1.110 B | 1.084 B | 1.520 B | 1.418 B | 1.323 B | 1.243 B | 1.301 B | 1.260 B | |
| Current Assets | 895.433 M | 858.947 M | 1.217 B | 963.671 M | 939.615 M | 893.493 M | 998.330 M | 884.043 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 18.304 M | 26.730 M | 20.407 M | 25.223 M | 26.485 M | 32.214 M | 49.651 M | 56.322 M | |
| Short Term Investments | 18.304 M | 26.730 M | 20.407 M | 25.223 M | 26.485 M | 32.214 M | 49.651 M | 56.322 M | |
| Total Receivables | 2.854 M | 4.023 M | 3.768 M | 4.906 M | 5.056 M | 6.491 M | 36.456 M | 36.427 M | |
| Current Cash | 874.275 M | 828.194 M | 1.193 B | 933.542 M | 908.074 M | 854.788 M | 912.223 M | 791.294 M | |
| Total Non-current Assets | 214.991 M | 225.511 M | 303.317 M | 454.218 M | 383.625 M | 349.856 M | 302.647 M | 375.546 M | |
| Property Plant Equipment | 25.868 M | 26.597 M | 27.921 M | 31.606 M | 33.194 M | 33.800 M | 32.760 M | 32.075 M | |
| Other Assets | 37.128 M | 36.989 M | 40.527 M | 40.920 M | 41.031 M | 42.363 M | 42.883 M | 70.957 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.110 B | 1.084 B | 1.520 B | 1.418 B | 1.323 B | 1.243 B | 1.301 B | 1.260 B | |
| Total liabilities | 229.877 M | 259.507 M | 284.530 M | 227.046 M | 218.352 M | 205.935 M | 250.808 M | 223.452 M | |
| Total current liabilities | 123.760 M | 131.132 M | 126.554 M | 103.383 M | 99.851 M | 91.953 M | 115.208 M | 97.912 M | |
| Accounts Payable | 7.515 M | 4.384 M | 5.154 M | 6.890 M | 11.634 M | 3.553 M | 7.452 M | 13.689 M | |
| Other liabilities | 46.120 M | 44.278 M | 43.958 M | 13.862 M | 12.919 M | 12.719 M | 38.853 M | 33.440 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 46.120 M | 44.278 M | 43.958 M | 13.862 M | 12.919 M | 12.719 M | 38.853 M | 33.440 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 880.547 M | 824.951 M | 1.236 B | 1.191 B | 1.105 B | 1.037 B | 1.050 B | 1.036 B | |
| Common stock | 75.823 M | 76.047 M | 81.267 M | 87.772 M | 88.185 M | 88.645 M | 90.478 M | 95.502 M | |
| Retained earnings | -950.551 M | -1.064 B | -1.177 B | -1.280 B | -1.404 B | -1.526 B | -1.658 B | -1.766 B |